Vesilute
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Vesilute is a Khavinson-school bioregulator, not a topical cosmetic. It came through the same source directory as the rest of the cosmetic-topical peptide cluster, but doesn’t actually belong to the cosmetic-skincare story.
What does it do in my body?
Vesilute is claimed to be a short peptide bioregulator that modulates gene expression in vascular endothelial cells, supporting vessel-wall integrity.
How can it help me?
- Where the science stands: Anecdotal: 0 studies, 0 human trials
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Vesilute was captured in the source profile. Safety is graded pending, reflecting the limited independent evidence base for this specific compound.
Regulatory status: Not a cosmetic ingredient. Framed within the Khavinson organ-peptide line, which is preclinical/Russian-school research territory rather than a regulated cosmetic or an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
No cosmetic/topical protocol applies. The source material captured here doesn’t include a standalone dosing protocol for Vesilute specifically; see the Khavinson bioregulator cluster for the general framework this peptide belongs to.
What should I avoid combining — and what's synergistic?
Vesilute doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A Khavinson-school bioregulator, not a topical cosmetic — it shares this cluster’s source directory but belongs, by mechanism and origin, to the Russian organ-peptide family covered in the Khavinson bioregulator family.
| Class | Khavinson-school bioregulator — vascular peptide (not a topical cosmetic, despite sharing this cluster’s source directory) |
| Mechanism (one line) | Claimed to modulate gene expression in vascular endothelial cells, supporting vessel-wall integrity |
| Evidence base | Anecdotal: 0 studies, 0 human trials |
| Safety record | Safety: pending |
| Regulatory status | Folded into the Khavinson organ-peptide line for framing purposes; not a cosmetic ingredient |
What it is
Vesilute is a Khavinson-school bioregulator, not a topical cosmetic. It came through the same source directory as the rest of the cosmetic-topical peptide cluster, but doesn’t actually belong to the cosmetic-skincare story.
How it works
Vesilute is claimed to be a short peptide bioregulator that modulates gene expression in vascular endothelial cells, supporting vessel-wall integrity.
What the research shows
Public profile grade: Anecdotal — 0 studies, 0 human trials.
OHM’s internal 0035 categorization pass folds Vesilute into the Khavinson organ-peptide line (alongside Livagen, Ovagen, Pancragen, Prostamax, and the rest), all graded Tier D / pending / provisional, noting “Russian-school preclinical with NO meaningful Western or independent Russian human RCT data” and recommending a single framework article rather than separate pages.
Status: belongs to the Khavinson bioregulator cluster, not the cosmetic-topical cluster — documented here only because it shared the source directory this cluster was originally built from. See the Khavinson bioregulator family for the fuller framework treatment of this peptide family.
Real-world protocol
No cosmetic/topical protocol applies. The source material captured here doesn’t include a standalone dosing protocol for Vesilute specifically; see the Khavinson bioregulator cluster for the general framework this peptide belongs to.
Side effects & management
No adverse-effect data specific to Vesilute was captured in the source profile. Safety is graded pending, reflecting the limited independent evidence base for this specific compound.
Regulatory status
Not a cosmetic ingredient. Framed within the Khavinson organ-peptide line, which is preclinical/Russian-school research territory rather than a regulated cosmetic or an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / pending / provisional, folded into the Khavinson organ-peptide line.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as belonging to the Khavinson bioregulator family, not the cosmetic-topical family.
Related: the Khavinson bioregulator family
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / pending / provisional, folded into the Khavinson organ-peptide line.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as belonging to the Khavinson bioregulator family, not the cosmetic-topical family.
Related: the Khavinson bioregulator family